Abstract
22-oxacalcitriol (OCT) is a vitamin D3 analog and a vitamin D receptor activator (VDRA) that is used as a drug for secondary hyperparathyroidism (SHPT) and has been available clinically in Japan since 2000. The pharmacological characteristics of OCT include rapid clearance from the systemic circulation compared to that of calcitriol, good tissue distribution, and relatively long retention in the nucleus in parathyroid cells. In clinical studies, OCT has been shown to decrease the parathyroid hormone (PTH) level with an effect equivalent to that of calcitriol. Other reports show that OCT produces superior improvement of bone metabolism compared to calcitriol. Treatment with ultrasound-guided direct injection of OCT into the parathyroid has also been attempted. In animal studies, OCT does not influence the blood Ca or P level and is less likely to promote progression of calcification in cardiovascular tissue. The influence of VDRAs including OCT on the progression of cardiovascular lesions and survival in SHPT patients requires further studies.
Keywords: Maxacalcitriol, percutaneous VDRA injection therapy, secondary hyperparathyroidism, vitamin D analogs, vitamin D receptor activator, 22-oxacalcitriol.
Current Vascular Pharmacology
Title:Clinical Uses of 22-Oxacalcitriol
Volume: 12 Issue: 2
Author(s): Masahide Mizobuchi and Hiroaki Ogata
Affiliation:
Keywords: Maxacalcitriol, percutaneous VDRA injection therapy, secondary hyperparathyroidism, vitamin D analogs, vitamin D receptor activator, 22-oxacalcitriol.
Abstract: 22-oxacalcitriol (OCT) is a vitamin D3 analog and a vitamin D receptor activator (VDRA) that is used as a drug for secondary hyperparathyroidism (SHPT) and has been available clinically in Japan since 2000. The pharmacological characteristics of OCT include rapid clearance from the systemic circulation compared to that of calcitriol, good tissue distribution, and relatively long retention in the nucleus in parathyroid cells. In clinical studies, OCT has been shown to decrease the parathyroid hormone (PTH) level with an effect equivalent to that of calcitriol. Other reports show that OCT produces superior improvement of bone metabolism compared to calcitriol. Treatment with ultrasound-guided direct injection of OCT into the parathyroid has also been attempted. In animal studies, OCT does not influence the blood Ca or P level and is less likely to promote progression of calcification in cardiovascular tissue. The influence of VDRAs including OCT on the progression of cardiovascular lesions and survival in SHPT patients requires further studies.
Export Options
About this article
Cite this article as:
Mizobuchi Masahide and Ogata Hiroaki, Clinical Uses of 22-Oxacalcitriol, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/15701611113119990023
DOI https://dx.doi.org/10.2174/15701611113119990023 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA Expression in Coronary Artery Disease
MicroRNA Deep Neck Infections
Infectious Disorders - Drug Targets Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Antitumor Titanium Compounds
Mini-Reviews in Medicinal Chemistry Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies
Reviews on Recent Clinical Trials Molecular Docking Studies Applied to a Dataset of Cruzain Inhibitors
Current Computer-Aided Drug Design Editorial (Hot Topic: From Genetic Testing to Personalized Medicine)
Cardiovascular & Hematological Agents in Medicinal Chemistry Is Beta-Blocker Treatment Associated with a Decrease in the Risk of Cancer
Letters in Drug Design & Discovery D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Copy Number Variations with Isolated Fetal Ventriculomegaly
Current Molecular Medicine Genes and Hypertension
Current Pharmaceutical Design Optimization of Cardiac Metabolism in Heart Failure
Current Pharmaceutical Design The Blood-Brain Barrier in NeuroAIDS
Current HIV Research Redox-Sensitive Smart Nanosystems for Drug and Gene Delivery
Current Organic Chemistry Long Chain Omega-3 Polyunsaturated Fatty Acids in Pediatric Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry Treatment of Chronic Pain with Drugs that Modulate Central Nervous System Serotonin and Norepinephrine
Current Drug Therapy Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design Methods for Docking Small Molecules to Macromolecules: A User’s Perspective. 2. Applications
Current Pharmaceutical Design